cerapedics
-
Biologics
Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft
The ASPIRE study is intended to evaluate the use of P-15L Bone Graft in transforaminal lumbar interbody fusion surgery in…
Read More » -
Biologics
Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery
Data published in ClinicoEconomics and Outcomes Research show that the novel i-FACTOR is not only cost-effective compared to autograft in…
Read More » -
Biologics
Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease
– P-15L Bone Graft is currently being studied in the Company’s ASPIRE IDE clinical trial – WESTMINSTER, Colo., April 29, 2021 /PRNewswire/…
Read More » -
Biologics
Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today…
Read More » -
Biologics
Cerapedics Announces Canadian Approval of its next-generation bone graft
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., September 15, 2020 — Cerapedics, a private…
Read More » -
Biologics
Cerapedics Announces FDA approval of an IDE supplement
WESTMINSTER, Colo., July 22, 2020 — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA)…
Read More » -
Biologics
Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide…
Read More » -
Biologics
Cerapedics Announces FDA Approval of PMA Supplement Based on Two-Year Clinical Data
WESTMINSTER, Colo., Nov. 18, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has…
Read More » -
Biologics
Cerapedics Announces Expansion of Colorado Headquarters
WESTMINSTER, Colo., July 8, 2019 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced the expansion of the company’s headquarters located in the Denver metropolitan…
Read More » -
Biologics
Cerapedics Appoints Patrick O’Connor as Vice President of Clinical and Market Development
WESTMINSTER, Colo., June 24, 2019 /PRNewswire/ –Cerapedics, a privately-held orthobiologics company, today announced the appointment of Patrick O’Connor as Vice President of Clinical and…
Read More » -
Biologics
Cerapedics Announces ISASS Issued a new Bone Grafting Policy Statement that Features i-FACTOR™ Peptide Enhanced Bone Graft
WESTMINSTER, Colo., March 6, 2019 /PRNewswire/ –Cerapedics, a privately-held orthobiologics company, today announced that the International Society for the Advancement of Spine…
Read More » -
Biologics
Cerapedics Announces First Patients Enrolled in IDE Clinical Trial of P-15L Bone Graft for Transforaminal Lumbar Interbody Fusion Surgery
WESTMINSTER, Colo., July 30, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that the first patients have been enrolled in…
Read More » -
Financial
Cerapedics Announces Closing of $22 Million Financing
WESTMINSTER, Colo., July 13, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that the company completed a $22 million financing led by KCK…
Read More » -
Biologics
Cerapedics Receives 2018 MedTech Breakthrough Award for Best New Surgical Technology Solution
WESTMINSTER, Colo., June 13, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that it has been selected as a winner…
Read More » -
Biologics
Cerapedics Announces Presentation of Results from the IVANOS Study of i-FACTOR™ Peptide Enhanced Bone Graft in Uninstrumented Lumbar Posterolateral Spine Surgery
WESTMINSTER, Colo., May 21, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced results from the IVANOS study evaluating i-FACTOR™ Peptide Enhanced…
Read More »